The Role of Quantitative Pharmacology in an Academic Translational Research Environment
- Jeffrey S. Barrett
- … show all 1 hide
Translational research is generally described as the application of basic science discoveries to the treatment or prevention of disease or injury. Its value is usually determined based on the likelihood that exploratory or developmental research can yield effective therapies. While the pharmaceutical industry has evolved into a highly specialized sector engaged in translational research, the academic medical research community has similarly embraced this paradigm largely through the motivation of the National Institute of Health (NIH) via its Roadmap initiative. The Clinical and Translational Science Award (CTSA) has created opportunities for institutions which can provide the multidisciplinary environment required to engage such research. A key component of the CTSA and an element of both the NIH Roadmap and the FDA Critical Path is the bridging of bench and bedside science via quantitative pharmacologic relationships. The infrastructure of the University of Pennsylvania/Children’s Hospital of Philadelphia CTSA is highlighted relative to both research and educational objectives reliant upon quantitative pharmacology. A case study, NIH-sponsored research program exploring NK1r antagonism for the treatment NeuroAIDS is used to illustrate the application of quantitative pharmacology in a translational research paradigm.
- A. K. Rustgi. Translational research: what is it? Gastroenterology 116(6):1285 (1999). CrossRef
- R. Rosell, M. Monzo, A. O’Brate, and M.Taron. Translational oncogenomics: toward rational therapeutic decision-making. Curr. Opin. Oncol. 14(2):171–179 (2002). CrossRef
- G. J. Kelloff, C. C. Sigman, and P. Greenwald. Cancer chemoprevention: progress and promise. Eur. J. Cancer. 35(14):2031–2038 (1999). CrossRef
- H. D. Humes. Translational medicine and the National Institutes of Health road map: steep grades and tortuous curves. J. Lab. Clin. Med. 146(2):51–54 (2005). CrossRef
- J. Mao. Translational pain research: bridging the gap between basic and clinical research. Pain 97(3):183–187 (2002). CrossRef
- S. C. Brown, and D. C. Park. Theoretical models of cognitive aging and implications for translational research in medicine. Gerontologist 43(Spec No 1):57–67 (2003).
- CDER. Innovation and stagnation: Challenge and opportunity on the critical path to new medicinal products. US Food and Drug Administration (2004).
- E. Zerhouni. Medicine The NIH Roadmap. Science 302(5642):63–72 (2003).
- J. Loscalzo. The NIH budget and the future of biomedical research. N. Engl. J. Med. 354(16):1665–1667 (2006). CrossRef
- H. Horig, E. Marincola, and F. M. Marincola. Obstacles and opportunities in translational research. Nat. Med. 11(7):705–708 (2005). CrossRef
- E. A. Zerhouni. Translational and clinical science—time for a new vision. N. Engl. J. Med. 353(15):1621–1623 (2005). CrossRef
- E. A. Zerhouni, and B. Alving. Clinical and translational science awards: a framework for a national research agenda. Translation Research 148(1):4–5 (2006). CrossRef
- J. Kaiser. Biomedicine. NIH funds a dozen ‘homes’ for translational research. Science 314(5797):237 (2006). CrossRef
- K. Garber. Translational institute unites unlikely partners at Penn. Science 317:968–969 (2007). CrossRef
- D. Dauphinee, and J. B. Martin. Breaking down the walls: thoughts on the scholarship of integration. Acad Med 75(9):881–886 (2000). CrossRef
- W. Z. Ho, A. Cnaan, Y. H. Li, H. Zhao, H. R. Lee, L. Song, and S. D. Douglas. Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages. AIDS Res. Hum. Retrovi 12:195–198 (1996). CrossRef
- W. Z. Ho, J. P. Lai, Y. Li, and S. D. Douglas. HIV enhances substance P expression in human immune cells. FASEB J. 16:616–618 (2002).
- J. P. Lai, W. Z. Ho, G. X. Zhan, Y. Yi, R. G. Collman, and S. D. Douglas. Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc. Natl. Acad. Sci. U. S. A. 98:3970–3975 (2001). CrossRef
- S. D. Douglas, W. Z. Ho, D. R. Gettes, A. Cnaan, H. Zhao, J. Leserman, J. M. Petitto, R. N. Golden, and D. L. Evans. Elevated substance P levels in HIV-infected men. AIDS 15:2043–2045 (2001). CrossRef
- D. L. Evans, J. Leserman, D. O. Perkins, R. A. Stern, C. Murphy, K. Tamul, D. Liao, C. M. van der Horst, C. D. Hall, and J. D. Folds. Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection. Am. J. Psychiatry 152:543–550 (1995).
- J. S. Barrett. Facilitating compound progression of antiretroviral agents via modeling and simulation. J. Neuroimmune Pharmacol 2:58–71 (2007). CrossRef
- The Role of Quantitative Pharmacology in an Academic Translational Research Environment
The AAPS Journal
Volume 10, Issue 1 , pp 9-14
- Cover Date
- Online ISSN
- Springer US
- Additional Links
- Model-based drug development
- NIH Roadmap
- Quantitative pharmacology
- Translational research
- Industry Sectors
- Jeffrey S. Barrett (1) (2) (3)
- Author Affiliations
- 1. Laboratory for Applied PK/PD, Clinical Pharmacology & Therapeutics Division, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- 2. Pediatrics Department, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- 3. Abramson Research Center, The Children’s Hospital of Philadelphia, Rm 916H, 3615 Civic Center Blvd, Philadelphia, Pennsylvania, 19104, USA